Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 double-blind randomized study of ATB200 + AT2221 versus alglucosidase alfa in late-onset Pompe disease
jRCT2080224804Phase 3Completed
- Sponsor
- Amicus Therapeutics
- Start
- Jul 2019
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes, Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in Pompe disease comparing ATB200 + AT2221 with Alglucosidase alfa + placebo (2 arms). Started Jul 2019; status: completed.
02
Drugs
cipaglucosidase alfamiglustat
03
Conditions
Pompe disease
Beyond the preview
Go deeper on jRCT2080224804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224804.